Navigation Links
Patients' underlying health linked to worse outcomes for melanoma, U-M study finds

ANN ARBOR, Mich. It's not how old but how frail patients are that can predict how well they will fare after a melanoma diagnosis. In fact, young patients in poor health may have worse outcomes than older patients in good shape.

A new study from the University of Michigan Comprehensive Cancer Center finds that patients with decreased core muscle density were more likely to see their cancer spread to distant parts of the body.

These findings may also support the idea that the patient's biological response to a tumor is important in controlling the spread of melanoma. Patients whose systems are less able to mount a response may be more prone to their cancer spreading.

The researchers believe that identifying those patients who are at higher risk of poor outcomes could impact treatment decisions, including the success of new immunotherapy drugs. And potentially, if this degenerative muscle loss, called sarcopenia, can be reversed, patients might have better outcomes.

The study, which appears online in Annals of Surgical Oncology, looked at 101 patients treated for stage III melanoma at the U-M Comprehensive Cancer Center. Researchers examined CT scans for each patient to measure the area and density of a core muscle called the psoas, which runs along both sides of the spine.

They found that patients with lower muscle density had significantly higher rates of their cancer returning regardless of factors such as the size of the tumor or the patient's age. Every 10 units of decreased muscle density translated to a 28 percent increase in recurrence. In addition, frailer patients had more complications from surgery to remove their cancerous lymph nodes.

Research has previously linked older age to worse outcomes in melanoma. These new results distinguish that it's the underlying vitality of the patient, not age, that really matters.

Many studies have looked at ways to reverse sarcopenia by focusing on diet and exercise.

"The big question is if we could reverse sarcopenia through better nutrition and exercise, would that lead to a decreased risk of recurrence in those patients?" says lead study author Michael S. Sabel, M.D., associate professor of surgery at the U-M Medical School.

In addition, researchers hope this information will help explain the limited success of new immunotherapy or cancer vaccine treatments.

"The data suggests that frailer patients may be less likely to respond to these forms of therapy. It is very possible that prior trials of vaccines or other immune therapies that didn't show an effect would have shown an effect if we had weeded out the patients unlikely to respond to therapy," Sabel says.

Researchers plan next to look at CT scans from patients treated in these trials to analyze whether the treatments were more effective in patients without sarcopenia.

Melanoma statistics: 68,130 Americans will be diagnosed with melanoma this year and 8,700 will die from the disease, according to the American Cancer Society


Contact: Nicole Fawcett
University of Michigan Health System

Related medicine news :

1. Transcatheter aortic valve implantation with the Edwards valve prosthesis in patients with low
2. What do patients receiving optimal medical therapy after a heart attack die from?
3. Potential benefits of remote follow-up of ICD patients
4. Clinical outcomes in PCI patients given sirolimus-eluting and everolimus-eluting stents
5. Patients are living longer with ICDs, but pacing impacts survival rates
6. Temporary ER staff poses increased safety risk to patients
7. Uninsured trauma patients are more likely to use the ED for follow-up care
8. Dialysis Patients Unprepared for Disasters, Study Contends
9. Achieving realistic physical activity goals benefits RA patients
10. Bone marrow transplantation may increase cancer resistance in patients
11. Clinical trial shows benefit to adding avastin to neoadjuvant chemotherapy in breast cancer patients
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology: